Abstract
Objective In previous studies, the protective effect of colonoscopy was generally stronger for distal than for proximal colorectal cancer (CRC). This study aimed to investigate whether the association of colonoscopy and CRC risk varies according to major molecular pathological features and pathways of CRC.
Design Population-based case-control study from Germany, including 2132 patients with a first diagnosis of CRC and information on major molecular tumor markers, and 2486 control participants without CRC. Detailed participant characteristics were collected by standardized questionnaires. Information on previous colonoscopy was derived from medical records. Polytomous logistic regression was used to calculate adjusted odds ratios (ORs) and 95% confidence intervals (95% CI) for the association between previous colonoscopy and subtypes of CRC.
Results Overall, we observed strong risk reduction of CRC after colonoscopy that was weaker for microsatellite instable (MSI) than for non-MSI CRC (p for heterogeneity <0.01), for CpG island methylator phenotype (CIMP) high CRC than for CIMP low/negative CRC (p het<0.01), for BRAF-mutated than for BRAF non-mutated CRC (p het<0.01), for KRAS non-mutated than for KRAS-mutated CRC (p het=0.04), and for CRC classified into the sessile serrated pathway than for CRC of the traditional pathway (p het<0.01). After colonoscopy with detection of adenomas, no risk reduction was found for sessile serrated pathway CRC, MSI and BRAF mutated subtypes.
Conclusion Our study extends the molecular understanding of existing differences in risk reduction of proximal and distal CRC reported by previous studies, and may imply important information for improving strategies for timely detection of relevant precursors.
What is already known about this subject?
Colonoscopy is an effective tool not only for early detection but also for prevention of colorectal cancer.
In previous studies, risk reduction after colonoscopy was generally stronger for cancer of the distal colon and rectum than for cancer of the proximal colon.
What are the new findings?
This observational study found variation of colorectal cancer risk reduction after colonoscopy according to major molecular subtypes characteristic of the proximal colon (MSI, CIMP-high, BRAF mutation), and for colorectal cancer potentially developing via the sessile serrated pathway.
How might it impact on clinical practice in the foreseeable future?
This study contributes to the identification of molecular characteristics and associated phenotypes of potentially missed or more aggressive precursors.
The study provides important information for improving strategies for a timely detection of relevant precursors at colonoscopy.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00011793
Funding Statement
This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, BR 1704/6-6, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1, BR 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, 01ER1505B, 01GL1712).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, BR 1704/6-6, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1, BR 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, 01ER1505B, 01GL1712).
Conflict of Interest: The authors declare that they have no conflict of interest. The funding organizations had no role in the collection, analysis, or interpretation of data.
Author roles: study concept, design (MH, JCC, HBr); acquisition of data (MH, HBl, MK, EH, WR, JCC, HBr); analysis, interpretation of data, manuscript draft (MH); critical revision of the manuscript (all authors); obtained funding (MH, HBl, MK, EH, WR, JCC, HBr); study supervision (MH, LJ, JCC, HBr).
Study registration: German Clinical Trials Register (DRKS00011793)
Data Availability
The data that support the findings of this study are available on request from the corresponding author.
Abbreviations
- CI
- confidence interval
- CIMP
- CpG island methylator phenotype
- CRC
- colorectal cancer
- het
- heterogeneity
- HRT
- hormone replacement therapy
- MSI
- microsatellite instability
- MSS
- microsatellite stable
- mut
- mutated
- NSAIDs
- non-steroidal anti-inflammatory drugs
- OR
- odds ratio
- UICC
- Union for International Cancer Control
